Immunicon Corp

Immunicon — Investor Presentation (June 2005)

15 slides from Immunicon's investor presentation, Jun 20, 2005

  1. Slide 1: Better Information for Better Healthcare

    Exhibit 99.1 Cellular Management June Forward This product results without 1 presentation 2005 todevelopment, limitation, Information Looking differ Presentation materially may Statements those for research contain Better detailed fromforward-looking programs Healthcare those in the anticipated Comp

  2. Slide 2: Investment Proposition

    Trading National Recent 52 Shares Market Immunicon Our Strategic Commercialization Compelling Superior FDA J&J Multiple Unique, Low Additional Extensive Continuing 3 2 week products executing incremental clearances outstanding Stock capitalization Information Symbol high high low Market value applic

  3. Slide 3: Entrepreneurial Management Team

    Entrepreneurial Name Ed Byron Michael Carrie Peter Leon Mark John Teresa James A Kits Cell Marker Enrichment Sample Standardized Off-Line Analysis 5 4 Systems Erickson Analysis and Verrant Terstappen, Scott Connelly, Position Wilcox, Murphy, Mulherin Hewett Lipcsey, Reagents Preservation Kagan Marke

  4. Slide 4: Circulating Tumor Cells: A Real-Time Biopsy

    Circulating Assess Monitor Phenotype & Determine Presence Most Isolation CellTracks® Sample Standardized Enrichment Kits Count Genotype and tumors Direct and Prognosis Collection Disease Marker of for Characterize Risk Diagnose Tumor epithelial Kits Specify Cancer are Technology Therapy Rare Assessm

  5. Slide 5: Circulating Tumor Cells Predict Survival in Metastatic Breast Cancer

    Circulating Before CTCs: 8 <5 Logrank 21.9 100% 3 4 1 2 0 Time 9 10.9 >5 %Probability ASCO NEJM <5 >5 2vs. CTCs 4Months at CTCs 4326from 90% Ap=0.3188 p=0.0397 p<0.0001 initiation 8Early Baseline 2004, 2005 pNew 10 n=90 n=87 <Baseline at 80% Tumor 12 0.0001 Draw of All Tool M ASCO (51%) (49%) 14 Sur

  6. Slide 6: CTCs vs. Current Radiologist Standard

    A3vs. Current Radiologist Subjective, CTCs 100% 0 Time S 26.9 3 1 11 6.4 10 15.3 19.9 2 PRO %Probability 2/New ASCO PR 4Months Months 243& 6from 90% Predict &p=0.3586 p=0.0518 p=0.1878 8Standard <5 >5 standard: 10 <5 2005 Baseline CTCs 80% semi-quantitative measures 12 CTCs Months of Outcome 14 T.Su

  7. Slide 7: Significant Early Predictive Value

    Significant Early Predictive A Meaningful “Real-Time Enables 225 Taxol 0 Herceptin Time Her2 131surrogate Int 2200 +++ + 3(weeks) evidence J4Her2 Oncol selection 175 5Her2 at 6Clinical marker surrogate Biopsy” 150 7 any - A21: 8of ++ 9time 125 of treatment 1111-1118, 10 in for Utility targeted from

  8. Slide 8: Real-Time Gene Expression Profiling and Research Programs

    “Real-Time Gene 50 13 31 30 # Pan 14 Current Colorectal Planned ~400 Prostate Research CTCs Other 15CTCs Normal Breast Prostate Colon Priority Cancer patient Expression are Clinical Cancer interim showed Cancer Cancer present Cancer Donors Report, Cancer Colon Biopsy” labeling analysis Development P

  9. Slide 9: Significant Market Opportunity and Follow-on Applications

    Many Follow-on Other RNA/DNA/protein Detection Circulating Autoimmune Cardiovascular Pharmaceutical Simple Significant Overall Cancer Prevalence: Incidence: Mortality: ~86% CellSearch™ 17 16 Cancer settings Product ofis cell U.S. all the of 570,280 Facts 1.37 applications Market Endothelial counting

  10. Slide 10: Strategic Alliance with Johnson & Johnson

    Salesfinishes, Strategic Key Immunicon J&J Revenue Access Reimbursement Existing Clinical Positive Large Veridex 19 18 Surgeons Oncologists Pathologists elements: and equity to provides data cost/benefit CPT shared Alliance Marketing J&J develops investment correlates sells codes technology, –(~30%

  11. Slide 11: Commercialization and Revenue Model

    Commercialization 26 Customers Quest SRL Reference Estimated Immunicon Revenue IMMC Gross Continuing Contribution ** 21 20 Assumes CellTracks® (Japan) Diagnostics profit margin share per Return labs in include R&D gets >$40 normal test ~$20 margin >$50 the %are AutoPrep ~31% 75 (to USA, investment f

  12. Slide 12: Lab and Hospital Payback Economics

    Comparison Lab CellSearch reimbursement ~$380 Medicare (before ~$200 Example System Instrumentation Cost Estimated Contribution Purchase Total Payback Note Analyzer 23 22 Immunicon per that tests/ work labor) purchase test analysis in of price/contribution II) ifreimbursement/ days/ tests Test month

  13. Slide 13: Capitalization and Cash Position

    (Dollars Capitalization Long Common 100,000,000 outstanding and 23 Additional Accumulated Other Total Cash Borrowing Milestones Publication Q2&Q3/04 Rx 25 24 23 Q1/05 23.2 December and burn stockholders’ capitalization term (2,935) in million cash stock, 510(k) guidance debt, paid thousands) capacit

  14. Slide 14: Near-term Milestones

    Near-term Launch Circulating Clinical RUO 510(k) San Bone Colorectal Prostate Immunicon Our Strategic Commercialization Compelling Superior FDA J&J Multiple Unique, Low Additional Extensive Continuing 27 26 Antonio products executing incremental clearances marrow commercialization for CellTracks res

  15. Slide 15: Contact Information

    Contact 3401 Masons Information Mill Road, Suite 100 Huntingdon Valley, Pennsylvania 19006 phone 215.830.0777 fax 215.830.0751 web www.immunicon.com 15

Immunicon — Investor Presentation (June 2005) on 6ix